In future, our radiogenomics study will involve several well-studied genomic signatures for GBM, such as the O6-methylguanine-DNA methyltransferase (MGMT) methylation status and the isocitrate dehydrogenase (IDH) 1/2 mutations. This evidence concerns the gene IDH3A and glioblastoma.